1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Research supporting the potential use of Bdellovibrio and/or Micavibrio bacterial predators as therapeutics against infections caused by Gram-negative antibiotic-resistant and priority threat pathogens. is sponsored by Defense Advanced Research Projects Agency (DARPA), Biological Technologies Office (BTO).
Research supporting the potential use of Bdellovibrio and/or Micavibrio bacterial predators as therapeutics against infections caused by Gram-negative antibiotic-resistant and priority threat pathogens.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.
gov Maintenance Calendar DARPA - Biological Technologies Office Document Type:Grants Notice Funding Opportunity Number:DARPA-BAA-14-51 Funding Opportunity Title:Pathogen Predators Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Cooperative Agreement Other Procurement Contract Category of Funding Activity:Science and Technology and other Research and Development Expected Number of Awards: Assistance Listings:12.
910 -- Research and Technology Development Cost Sharing or Matching Requirement:No Original Closing Date for Applications:Dec 09, 2014 Current Closing Date for Applications:Dec 09, 2014 Archive Date:Jan 08, 2015 Estimated Total Program Funding: Eligible Applicants:Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Additional Information on Eligibility: ## Additional Information Agency Name:DARPA - Biological Technologies Office Description:DARPA is soliciting proposals for research supporting the potential use of Bdellovibrio and/or Micavibrio bacterial predators as therapeutics against infections caused by Gram-negative antibiotic-resistant and priority threat pathogens.
Link to Additional Information:FedBizOpps. gov link. Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes.
To continue working, click on the "OK" button below. This is being done to protect your privacy. Unsaved changes will be lost.
According to the current listing, eligibility includes: Not specified, but generally open to research organizations and institutions. Confirm the full requirements in the official notice before applying.
Research supporting the potential use of Bdellovibrio and/or Micavibrio bacterial predators as therapeutics against infections caused by Gram-negative antibiotic-resistant and priority threat pathogens. is funded by Defense Advanced Research Projects Agency (DARPA), Biological Technologies Office (BTO). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Biological Technologies is sponsored by Defense Advanced Research Projects Agency (DARPA), Biological Technologies Office (BTO). Supports revolutionary research leveraging biological properties/processes to advance national security and protect warfighters; excludes incremental improvements. Key focus areas include advanced machine learning and AI for biological data and systems, combat casualty care, human performance optimization, bio-inspired materials, sensors, manufacturing, agricultural, ecological, and environmental security, biosafety, biosecurity, next-generation surveillance, and biomedical and biodefense technologies. Foreign companies may be eligible as DARPA aims for international collaboration for national security.
DARPA's Biological Technologies Office (BTO) Office-Wide Broad Agency Announcement (HR001126S003) seeks abstracts and proposals that leverage biological properties and processes to revolutionize the ability to protect warfighters, with an explicit emphasis on applying artificial intelligence and machine learning across biological science. Priority research areas include machine learning and AI applications, combat casualty care, human performance optimization, materials/sensors/processing, agricultural and environmental solutions, security and surveillance, and biomedical and biodefense initiatives. Abstracts are accepted on a rolling basis until September 30, 2026.
On June 3, 2026, four DARPA Biological Technologies Office SBIR topics close simultaneously — SWiFT, BARK, EXPOSITION, and Medical Swarm Robotics. Combined Phase I plus Phase II potential exceeds $6 million per company, and together they sketch a coherent strategy of distributed, autonomous, dual-species combat casualty care that depends on small businesses, not primes, to actually build.
Read articleDARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read articleDARPA BTO pre-released four FY26 SBIR/STTR topics on April 30, 2026, with proposals due June 3. Two topics — SWiFT and EXPOSITION — offer Direct-to-Phase-II awards up to $1.5M, bypassing the standard Phase I gate. Here is what each topic is actually solving, why the DP2 structure matters, and how small biotech, surgical robotics, and battlefield-medicine teams should decide whether to compete.
Read article